UBS Says Fresenius’s Biopharma Performance Should Be Well Received
UBS analysts say Fresenius’s adjusted third-quarter earnings came in ahead of expectations, citing strong biopharma performance.
UBS analysts say Fresenius’s adjusted third-quarter earnings came in ahead of expectations, citing strong biopharma performance.